This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jun 16;379(9833):2222-3.

doi: 10.1016/S0140-6736(12)60769-7. Epub 2012 Jun 9.

Type 2 diabetes: which drug as add-on to metformin?

Affiliations

PMID: 22683136
DOI: 10.1016/S0140-6736(12)60769-7

Comment

Type 2 diabetes: which drug as add-on to metformin?

Sten Madsbad. Lancet. 2012.

. 2012 Jun 16;379(9833):2222-3.

doi: 10.1016/S0140-6736(12)60769-7. Epub 2012 Jun 9.

Author

Affiliation

¹ Department of Endocrinology, Hvidovre Hospital and University of Copenhagen, 2650 Hvidovre, Denmark. sten.madsbad@hvh.regionh.dk

PMID: 22683136
DOI: 10.1016/S0140-6736(12)60769-7

No abstract available

PubMed Disclaimer

Comment on

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, Festa A, Kiljański J, Sapin H, Trautmann M, Schernthaner G. Gallwitz B, et al. Lancet. 2012 Jun 16;379(9833):2270-8. doi: 10.1016/S0140-6736(12)60479-6. Epub 2012 Jun 9. Lancet. 2012. PMID: 22683137 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information